Jian Gu

1
BUS6900 IP Strategy and ManagementNOVARTIS
GROUP

• Jian Gu
• Sedem Yener
• Elias Jaime Porras

2
Context

• About Novartis Company
• IP Portfolio
• IP strategy and management
• Future plan for Novartis Company

3
About Novartis Company

• multinational pharmaceutical company
• offers a wide range of healthcare products
  through our Pharmaceuticals, Vaccines and
  Diagnostics, Sandoz and Consumer Health
  Divisions.
• a full member of the European Federation of
  Pharmaceutical Industries and Associations.
• was created in 1996 from the merger of Ciba-Geigy
  and Sandoz Laboratories.
• Main local is Switzerland.
• In 1998 the company made headlines with its
  biotechnology licensing agreement with the UC
  Berkeley Department of Plant and Microbial
  Biology.

4
Details

• CEO Dr. Daniel Vasella, M.D.
• Employees 98200
• Market Cap 107,150,055,000
• Auditor PriceWaterHouse Cooperation A.G.
• Gross Margin 71.3
• Profit Margin 20.3
• EBIT Margin 20.9
• Return on Equity 23.9
• Return on Capital 22.9
• Return on Assets 14.8

5
Pharmaceuticals Products of Novartis Company

• Diovan- 5.0 B sales (2007)- Hypertension
• Gleevec - 3.1 B- for Chronic myeloid leukemia
• Zometa- 1.3 B (2007)- Cancer complications
• Sandostatin - 1.0 B (2007) - Acromegaly
• Sandimmun Neoral- 944 M (2007)- Transplantation
• Femara- 937 M (2007)- Breast cancer
• Lotrel- 748 M (2007)- Hypertension
• Voltaren- 747 M (2007)- Inflammation
• Trileptal- 692 M (2007)- Epilepsy

• Lescol- 665 M (2007)- cholestrol
• Exelon- 632 M (2007)- Alzheimer's disease
• Comtan- 420 M (2007)- Parkinson's disease
• Tegretol- 413 M (2007)- Epilepsy
• Lucentis- 393 M (2007)- Age-related macular
  degeneration
• Ritalin- 375 M (2007) - ADD
• Exjade- 357 M (2007) Iron chelator
• Tobramycin- 273 M (2007)- Cystic fibrosis
• Termalgin - (Paracetamol and compounds.) -
  Treatment of fever and light pain.

6
Major therapeutic areas

• autoimmunity/transplantation/ inflammatory
  disease
• cardiovascular disease
• diabetes
• gastrointestinal disease
• infectious diseases
• musculoskeletal disease
• neuroscience
• oncology
• ophthalmology
• respiratory disease

7
Novartis IP portfolio!!!

• involves coordination and quality control of
  biologics patenting and freedom-to-operate
  analysis across all disease areas, platforms, and
  functions within NIBR.
• is Director of Intellectual Property

• John T. LiPatents, Head, Biology Biologics,
  Novartis Institutes forBiomedical
  ResearchNovartis

8
Novartis IP portfolio and Its Process!!!

• operates in 140 countries and currently has 75
  new treatments in the pipeline
• More than 12,000 US Granted Patents
• Patent Mapping Reports provide specific and
  detailed insights into patenting activities of
  specific Fortune 500, NASDAQ and SampP 500
  organisations
• Is gearing up to break new CSR ground, with a
  funding proposal for neglected disease research
  that advantages IP rights to strike a balance
  between corporate return on investment and the
  provision of vital treatments to penniless
  developing countries.

9
Novartis IP portfolio and Its Process!!!

• The International Patent Classification (IPC) is
  a hierarchical system in which the whole area of
  technology is divided into a range of sections,
  classes, subclasses and groups.
• have undertaken a concordance (matching) of IPC
  (International Patent Classification ) and (US
  Patent Classification) UPC to NAICS (North
  American Industrial Classification System -this
  new, uniform, industry-wide classification system
  has been designed as the index for statistical
  reporting of all economic activities of the U.S.,
  Canada, and Mexico).

10
Future Planning

• Novartis Buys Additional 51.7 Stake in Speedel
  company.
• Make e-business partnership World Online and
  Novartis plan together to build initially a
  pan-European portal and an e-commerce platform
  that will become the first of its kind within the
  healthcare and wellness arena.
• 30 Increase In US Supplies Of Fluvirin Influenza
  Vaccines And Delivery Of 40 Million Doses.
• will be replaced by two Novartis execs who will
  oversee development in newly created roles

11
Thank you!!!
Any Question?